SEC For	m 4																	
FORM 4 UNITED				) STA	STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See						NT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940									OMB Number:         3235-0287           Estimated average burden            hours per response:         0.5			
1. Name and Address of Reporting Person* HEALY JAMES					2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Y-mAbs Therapeutics, Inc.</u> [ YMAB ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (nive title Other (cpecify					
	C/O SOFINNOVA INVESTMENTS INC.				3. Date of Earliest Transaction (Month/Day/Year) 06/23/2020								<ul> <li>Officer (give title Other (specify below)</li> <li>below)</li> </ul>					
(Street)	3000 SAND HILL ROAD, BLDG. 4, SUITE 2 Street) MENLO PARK CA 94025			UC	4.1	Line)								vidual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(S	,	(Zip)			Person												
Table I - Non-Deriv.       1. Title of Security (Instr. 3)       2. Transz Date (Month/D)					actior	ction 2A. Deemed Execution Date			ar) Code (Instr. 5)			ed (A) or tr. 3, 4 and	5. Amount of 6. O Securities Forr Beneficially (D) o		Form:	Direct II Indirect E str. 4) C	. Nature of ndirect seneficial Ownership nstr. 4)	
									luired, Dis s, options				Owned					
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date ecurity or Exercise (Month/Day/Ye		3A. Deemed Execution D if any (Month/Day	Date, T	4. Transac Code (Ir r) 8)				6. Date Exerc Expiration D (Month/Day/ <sup>1</sup>	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactiv (Instr. 4)	e s dly g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownershij (Instr. 4)	
				c	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Non- Employee Stock Option (right to buy) <sup>(1)</sup>	\$48.67	06/23/2020			A		16,000		07/23/2020 <sup>(2)</sup>	06/23/2030	Common stock	16,000	\$0	16,00	0	D		

Explanation of Responses:

1. Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.

2. The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service on the board of directors of Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting.

<u>/</u>	<u>s/ James Healy</u>
*	* Signature of Penorting Person

06/24/2020

Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.